SEP 8 9 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Shohei Koide

Title:

ARTIFICIAL ANTIBODY POLYPEPTIDES

Docket No.:

17027.003US1

Serial No.: 09/903,412

Filed:

July 11, 2001

Group Art Unit: 1639

Examiner:

Teresa D. Wessendorf

Commissioner for Patents

P.O.Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the attached items (as indicated with an "X"):

X A return postcard.

X A Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.), and copy of one reference.

VIKSNINS HARRIS & PADYS PLLP

Customer Number 53137

Ann S. Viksnins Reg. No. 37,748

CERTIFICATE UNDER 37 CFR 1.8: The undersigned certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 26 day of September 2005.

Lynda Mau

Signature Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Shohei Koide

Examiner: Teresa D. Wessendorf

Serial No.:

09/903,412

Group Art Unit: 1639

Filed:

July 11, 2001

Docket No.: 17027.003US1

Title:

ARTIFICIAL ANTIBODY POLYPEPTIDES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In accordance with the duty imposed by 37 C.F.R. § 1.156, and in accordance with 37 C.F.R. §§ 1.97 et. Seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record. Pursuant to provisions of MPEP 609, Applicant requests that a copy of the Form PTO-Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. If necessary, please apply any charges or credits to Deposit Account No. 50-3503.

<u>CERTIFICATE UNDER 37 CFR 1.8</u>: The undersigned certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this <u>A</u> day of <u>September</u> 2005.

Typed or Printed Name of Person Signing Certificate

Signature

Serial Number: 09/903,412 Filing Date: July 11, 2001

Title: ARTIFICIAL ANTIBODY POLYPEPTIDES

Dkt: 17027.003US1

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

SHOHEI KOIDE

By his Representatives,

VIKSNINS HARRIS & PADYS PLLP P.O. Box 111098 St. Paul, MN 55111

(952) 876-4091

Date 26 Systel 2005

By_ Ann S. Viksnins

Reg. No. 37,748

Sheet	1	of	1

IA	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17027.003US1	Application No. 09/903,412	
	Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Shohei Koide		
3	(Use several sheet) (37 🚀 §1.98(b))	ets if necessary)	Filing Date July 11, 2001	Group Art Unit 1639	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2003/0134386	07/17/2003	Koide			

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Transla	ation
Initial	D di	Number	Date	Patent Office	Class	Subclass	Yes	No
							<u> </u>	
						-		
							abstract	

Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
	AB	Dickinson et al., "Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor," J. Biol. Chem., 1997, 272:19875-19879			

Examiner Signature	Date Considered		
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with		
next communication to applicant.			